https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34560 Wed 27 Mar 2019 10:17:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33561 Wed 21 Nov 2018 09:47:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40865 12 years of age with a chronic cough due to asthma or NAEB. Eligible studies were identified in MEDLINE, CENTRAL, and SCOPUS and assessed for relevance and quality. Guidelines were developed and voted upon using CHEST guideline methodology. Results: Of the citations reviewed, 3/1,175, 53/656, and 6/134 were identified as being eligible for inclusion in the three systematic reviews, respectively. In contrast to established guidelines for asthma therapies in general and the inclusion in some guidelines for a role of biomarkers of airway inflammation to guide treatment in severe disease, the evidence of specific benefit related to the use of non-invasive biomarkers in patients with chronic cough due to asthma was weak. The best therapeutic option for cough in asthma or NAEB is inhaled corticosteroids followed by leukotriene receptor antagonism. Conclusions: This guideline offers recommendations on the role of non-invasive measurements of airway inflammation and treatment for cough due to asthma or NAEB based on the available literature, and identifies gaps in knowledge and areas for future research.]]> Tue 19 Jul 2022 14:10:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33625 Mon 26 Nov 2018 12:48:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36789 Mon 06 Jul 2020 11:38:40 AEST ]]>